Essais liés10clinical trials
VilleLondonlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06643481

Ouvrir le site du centre

Essais cliniques associés

10
MoléculeIndication / populationPhaseNCTTitreStatut
rapcabtagene autoleucel Lupus Phase 2 NCT06581198 A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) ACTIVE_NOT_RECRUITING
Remibrutinib (Blinded) SEP Phase 3 NCT07225504 REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis RECRUITING
VHB937 Sclérose latérale amyotrophique Phase 2 NCT06643481 ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) ACTIVE_NOT_RECRUITING
YTB323 Myasthénie Phase 1/2 NCT06704269 Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis ACTIVE_NOT_RECRUITING
Remibrutinib (Blinded) Myasthénie Phase 3 NCT06744920 RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis RECRUITING
Iptacopan Myasthénie Phase 3 NCT06517758 A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. ACTIVE_NOT_RECRUITING
Remibrutinib oral treatment SEP Phase 3 NCT06846281 Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. RECRUITING
Interferon beta-1a SEP Phase 3 NCT01892722 Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Ofatunumab SEP Phase 4 NCT06444113 KATHAROS — Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis ACTIVE_NOT_RECRUITING
RAD001 Épilepsie Phase 3 NCT01713946 A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures COMPLETED